BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24504597)

  • 1. Preparation and evaluation of a CD13/APN-targeting and hydrolase-resistant conjugate that comprises pingyangmycin and NGR motif-integrated apoprotein.
    Li B; Zheng YB; Li DD; Zhen YS
    J Pharm Sci; 2014 Apr; 103(4):1204-13. PubMed ID: 24504597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of antibody-targeted chemotherapy with pingyangmycin on prostate cancer cells in vitro].
    Chen WZ; Zhang Y; Liang CS; Xie Y; Wen QQ; Gao X
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):406-8. PubMed ID: 18359702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of the conjugate composed of a human monoclonal antibody and pingyangmycin on mammary cancer].
    Wang WG; Wang SH; Xue YC; Zhen YS
    Yao Xue Xue Bao; 1995; 30(8):583-7. PubMed ID: 8571778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody].
    Dai Y; Liu XJ; Zhen YS
    Yao Xue Xue Bao; 2006 Jan; 41(1):41-6. PubMed ID: 16683526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of monoclonal antibody-pinyangmycin conjugate in experimental regional targeting therapy of tumor].
    Wang WG; Xu LN; Zhang SH; Xue YC; Zhen YS
    Yao Xue Xue Bao; 1997 Sep; 32(9):669-74. PubMed ID: 11596291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer (68)Ga-NOTA-c(NGR).
    Máté G; Kertész I; Enyedi KN; Mező G; Angyal J; Vasas N; Kis A; Szabó É; Emri M; Bíró T; Galuska L; Trencsényi G
    Eur J Pharm Sci; 2015 Mar; 69():61-71. PubMed ID: 25592229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preparation of lymphatic targeting dosage form: pingyangmycin absorbed on activated carbon nanoparticles].
    Sun ML; Wen YM; Wang CM; Li LJ; Wang XY
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Jun; 22(3):183-5. PubMed ID: 15293458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates.
    Liu X; Zhen Y
    Chin Med Sci J; 2002 Mar; 17(1):1-6. PubMed ID: 12894876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of verapamil on pingyangmycin-induced cytotoxicity and apoptosis in KB cells.
    Ho YC; Tai KW; Chang YC
    Oral Dis; 2007 Jan; 13(1):40-4. PubMed ID: 17241428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
    Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
    Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of carbonic anhydrase 9 as a contributor to pingyangmycin-induced drug resistance in human tongue cancer cells.
    Zheng G; Zhou M; Ou X; Peng B; Yu Y; Kong F; Ouyang Y; He Z
    FEBS J; 2010 Nov; 277(21):4506-18. PubMed ID: 21040473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
    Gong JH; Liu XJ; Li Y; Zhen YS
    Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13).
    Cui SX; Zhang HL; Xu WF; Qu XJ
    Eur J Pharmacol; 2014 Jul; 734():50-9. PubMed ID: 24726845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NGR peptide ligands for targeting CD13/APN identified through peptide array screening resemble fibronectin sequences.
    Soudy R; Ahmed S; Kaur K
    ACS Comb Sci; 2012 Nov; 14(11):590-9. PubMed ID: 23030271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibition of the growth of hepatoma and hepatic metastasis by pingyangmycin conjugated with Fab' fragment of monoclonal antibody].
    Liu X; Shang B; Liu X
    Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(4):201-4. PubMed ID: 11798873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.